Unlearn

The company's technology focuses on generative machine learning methods to create patient digital twins that can forecast how a patient's health may change over time and compare potential health outcomes. By partnering with pharma and biotech industry, Unlearn AI seeks to accelerate clinical drug development and full enrollment in AI-powered clinical trials.

Unlearn AI is a California-based company that leverages Artificial Intelligence (AI) to facilitate faster and more efficient drug development processes. By utilizing generative machine learning methods, the company has developed a way to create patient digital twins which can simulate 'what if?' scenarios. This allows them to predict individual health outcomes and forecast how a patient's health may change over time, as well as estimate relative treatment effects. With this technology, Unlearn AI not only aims to speed up drug development but also put patients first by enabling predictive analysis for better clinical decision-making.

In order to achieve their mission of advancing AI technology in healthcare, Unlearn AI partners with innovators in the pharma and biotech industry. Through this collaboration, they hope to eliminate trial and error in medicine while simultaneously accelerating clinical drug development and achieving full enrollment in AI-powered clinical trials faster. Currently, they are building the preeminent AI company in healthcare and looking for innovative individuals who share their vision of building the future in medicine.

By leveraging their advanced technology through partnerships with the pharmaceutical industry, Unlearn AI is on track towards revolutionizing medical treatments by providing personalized care for